argenx reports Phase I/II cancer data of CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) reported data from two Phase I/II trials of ARGX-110 at the American Society of Hematology (ASH) meeting in Atlanta.

Preliminary data

Read the full 242 word article

User Sign In